AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

RCT of EFTR Versus STER for GIST Treatment

RecruitingNAAges 18 Years - 75 YearsAllChinese University of Hong Kong
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Endoscopic resection has been increasing utilized as the treatment for small size gastrointestinal stromal tumors (GIST), of which the best resection method has not been identified. We aim to compare the outcomes of endoscopic full thickness resection (EFTR) versus submucosal tunnelling endoscopic resection (STER) for clinical small gastric GIST. We hypothesize that EFTR could achieve better complete margin negative resection than STER without increase in adverse event. This is an international multi-center double blinded randomized controlled trial involving four high volume centers from Hong Kong, mainland China, India and Japan. Adult patients with clinical 1.0-3.Scm gastric GIST undergoing endoscopic resection would be recruited. Patients would be randomized to undergo EFTR (intervention) or STER (Control) by expert endoscopists under general anaesthesia according to well published

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Consecutive adult patients age \>=18 and \<=75 with a clinical diagnosis of gastric GIST who opted for endoscopic resection would be screened for eligibility. Inclusion Criteria: * Presence of gastric subepithelial tumor on diagnostic upper endoscopy, and * Diagnostic EUS and CT scan with intravenous contrast suspicious of GIST arising from muscularis propria layer, size with maximum diameter \>=1.0cm and \<= 3.5cm, and * Absence of high risk features, including irregular margins, invasion to surrounding organs, lesion hypervascularity, and * Endoscopic morphology and location deemed feasible with both EFTR and STER by an expert endoscopist, or * Histological confirmation of GIST through EUS guided fine needle biopsy (Optional, based on recommendation from guidelines) Exclusion Criteria: * Patients with tumors deemed not suitable for endoscopic resection (Either EFTR or STER), due to unfavourable location, high risk morphology, or any other reasons. * Patients with multiple tumors. * Patients unable or unwilling to provide consent. * Previous esophageal or gastric surgery. * Patients with significant cardiorespiratory comorbidities which may limit their ability to undertake general anesthesia for the procedure, including ASA grade III or above. * Pregnant women or those planning pregnancy or breastfeeding women. * Uncorrectable coagulopathy defined by international normalized ratio (INR) \> 1.5 or platelet count \< 50000/ยตl. * Patients on double anti-platelet agents or anti-coagulation (Warfarin, heparin or other direct oral anticoagulants)
๐Ÿ’Š

What it tests

  • Endoscopic full thickness resection (EFTR) / Exposed non-tunneling EFTR
  • Submucosal Tunneling Endoscopic Resection (STER) / Exposed tunneling EFTR
๐Ÿ“

Where

4 sites
Department of Gastroenterology, Zhongshan Hospital of Fudan University
Shanghai, China
Department of Surgery, Faculty of Medicine, the Chinese University of Hong Kong
Hong Kong, Hong Kong
Asian Institute of Gastroenterology
Hyderabad, India
Osaka International Cancer Institute
Osaka, Japan
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy